What Is Beta Blocker Selectivity and Why Does It Matter?

Beta blockers all quiet the effects of adrenaline, but they don’t all do it in the same places. Selectivity is the word for how narrowly a given drug aims at the heart instead of also reaching the lungs and blood vessels. That makes the label matter less for how well the drug protects your heart than for which side effects you might notice. And a selective drug stays focused only at the doses it was designed for.

Beta-1 and Beta-2 Sites and What Blocking Each One Does

Adrenaline and noradrenaline act on the body through docking points called beta receptors.¹ Beta-1 receptors sit mainly in the heart, where adrenaline speeds the heartbeat and makes it pump harder. Beta-2 receptors sit mainly in the airways and blood vessel walls, where adrenaline relaxes and opens them. Blocking beta-1 slows the heart and lowers its oxygen demand, which is why these drugs help angina and blood pressure.² A beta blocker sits in those sites and stops adrenaline from using them, so what the drug does depends on which sites it occupies.

Non-selective beta blockers block beta-1 and beta-2 receptors to an equal degree.³ Selective, or “cardioselective,” beta blockers have a stronger pull toward beta-1 than beta-2.⁴ Doctors judge how heart-focused a drug is by how much more strongly it binds beta-1 than beta-2.⁵

A non-selective drug dampens adrenaline’s effects on airways and vessels too, while a selective drug leaves most beta-2 sites working. “Selective” means “prefers,” not “only,” a point that matters once doses go up. Blocking beta-2 in the airways and vessels is the main source of the extra side effects of non-selective drugs.⁶

Which Beta Blockers Are Selective and Which Are Not

Third-generation drugs block the heart’s beta-1 sites and also widen blood vessels by blocking alpha-1 receptors or switching on beta-3 receptors.¹⁰ Nebivolol and carvedilol can also trigger the vessel lining to release nitric oxide, a natural vessel relaxer.¹¹ Carvedilol, though, is not heart-selective, since it blocks beta-2 as well.¹² Side effects tend to fall from the first generation to the second, and fall further with the third.¹³

So “newer” and “selective” are different things. Nebivolol is both heart-selective and vessel-widening, while carvedilol is not heart-selective.

To find your drug’s group, look up the generic name on your box rather than the brand name. Most names end in “-olol,” so the ending won’t tell you the group, but a pharmacist can confirm it.

Asthma and COPD Are Where Selectivity Matters Most

Blocking beta-2 sites in the airways lets them narrow, and non-selective first-generation drugs can cause airway tightening.¹⁴ Blocking beta-2 also blunts reliever inhalers, which work by switching those same sites on. That’s why non-selective drugs weaken the inhaler more, while selective drugs, which leave most beta-2 sites free, interfere less.

A first dose of a selective beta blocker lowered breathing capacity by about 7% on average in people with asthma.¹⁵ About 1 in 8 people with asthma had a drop of 20% or more, a fall large enough to notice.¹⁶ Non-selective drugs did worse, cutting breathing capacity about 10% and halving the boost from a reliever inhaler.¹⁷ Selective drugs reduced the reliever’s effect by about a tenth, so the inhaler still mostly works.¹⁸

Starting a beta blocker with asthma usually means a selective drug at a low dose. The first days are when tightening is most likely, so watch for wheeze or for needing your reliever more often. Keep your inhaler with you, knowing it still works on a selective drug. If new breathlessness appears, report it promptly rather than stopping the drug on your own.

Taken for 3 to 28 days, selective beta blockers caused no change in breathing, symptoms or inhaler use in mild to moderate airway disease.¹⁹ People with COPD showed no meaningful change in breathing on selective beta blockers.²⁰ Selective beta blockers should not be withheld from people with mild to moderate COPD or reactive airways who need them.²¹ Severe or unstable asthma remains a reason for extra caution.

How Dose Can Undo Selectivity

Selective beta blockers are only relatively focused on beta-1.²² At higher doses they block more beta-2 sites as well.²³ A high dose of a selective drug can therefore start to behave like a non-selective one. A person who tolerated a low dose without lung symptoms can’t assume the same holds after an increase.

Genes can raise your effective dose, too. People whose liver breaks down metoprolol slowly can end up with roughly five times as much of the drug in their blood from the same dose.²⁴ Their heart rate falls a few beats per minute more.²⁵ Slow processors tend to need lower metoprolol doses.²⁶

If your dose is being raised, side effects you didn’t have at a low dose, like wheeze or cold hands, can appear as it climbs. Tell your doctor about these changes rather than assuming the drug suits you at any dose. If you feel dizzy or your pulse is unusually slow on metoprolol, mention that too. Genetic testing exists but isn’t routine; adjusting the dose by your response is the usual approach.

Cold Hands, Blood Sugar, Cholesterol and Mood

Selectivity reduces side effects from blocking beta-2 outside the heart, such as cold hands and feet and erectile difficulties.²⁷ Non-selective drugs like propranolol have been reported to worsen Raynaud’s, while selective ones like metoprolol are less likely to.²⁸ Yet single doses of either type didn’t reduce finger blood flow in people with Raynaud’s.²⁹ Neither type worsened leg pain on walking in people with narrowed leg arteries.³⁰ People with severe Raynaud’s should still use any beta blocker cautiously.³¹ If cold fingers started or worsened after you began the drug, tell your prescriber, who can consider a selective or vessel-widening alternative rather than leaving you to tolerate them.

Older beta blockers that don’t widen vessels are linked with slightly worse blood sugar and fat levels.³² Vessel-widening beta blockers have more favorable effects on blood sugar and fats.³³ Most beta blockers raise triglycerides and lower “good” HDL cholesterol, and selective and non-selective drugs differ little in this.³⁴

Fears that beta blockers are unsafe for people with diabetes are largely a misconception, though they can blunt warning signs of low blood sugar such as a racing heart.³⁵ Vessel-widening drugs may be considered when sugar control is a worry. Keep checking your blood sugar as you usually do, and tell your care team if your readings change after starting.

Highly fat-soluble beta blockers such as propranolol are more often linked with effects on the brain.³⁶ Vivid dreams or low mood on propranolol may ease on a less fat-soluble drug. Brain effects depend on fat-solubility, a separate property from selectivity.

Some beta blockers, such as pindolol and acebutolol, gently stimulate the receptor while blocking it.³⁷ These partial-stimulating beta blockers slow the resting heart less.³⁸

Heart Protection Is Similar Across the Groups

In heart failure, beta blockers cut deaths from any cause by about a third.³⁹ Carvedilol, which is non-selective, and bisoprolol and long-acting metoprolol, which are selective, each cut deaths by about 34-35% in major trials.⁴⁰ The benefit looks like a family effect, seen across different beta blocker types.⁴¹ The choice between groups is usually about your other conditions and side effects, not heart protection.

Your doctor may pick one drug over another for those reasons. Asthma or COPD pushes toward a selective drug. Diabetes or high blood pressure may favor a vessel-widening one. Switching from one proven drug to another wouldn’t be expected to change the protection, but don’t switch on your own, since stopping a beta blocker suddenly can strain the heart.

Heart failure is a special case. Only certain beta blockers have been proven in heart failure trials, so the drug is chosen from that list rather than at random. A drug that lowers blood pressure well isn’t automatically proven to help a failing heart, so if you have heart failure, the name of the drug matters more than its group.

Propranolol for Anxiety, Tremor and Migraine

Propranolol and some other beta blockers work well for benign essential tremor and for preventing migraine.⁴² They also help with anxiety and alcohol withdrawal.⁴³ These benefits mainly come from blocking adrenaline’s effects outside the brain, such as a pounding heart and shaking hands.⁴⁴

That’s why propranolol suits the physical symptoms of anxiety: the racing heart, sweating and trembling are quieter. It doesn’t treat worry or fear themselves, so it isn’t a substitute for other anxiety treatment when that is needed.

Because propranolol is non-selective, people with asthma face the airway risks described above, so mention any asthma before starting, even for occasional use before a performance. Its fat-solubility explains the vivid dreams or tiredness some users notice.

Eye Drops Can Act Like a Tablet

Timolol glaucoma drops are non-selective and drain through the nose into the bloodstream.⁴⁵ About three-quarters of a dose can reach the blood, peaking within about 15 minutes.⁴⁶ That route skips the liver’s first-pass breakdown that partly reduces tablets, so a drop can have more effect than its size suggests.

Drops can therefore cause the same side effects as timolol tablets.⁴⁷ Reported effects include breathing trouble in people with airway disease, a slow pulse, fatigue and depression.⁴⁸

To reduce how much reaches the body, press gently on the inner corner of the eye for a minute after a drop, and close your eye rather than blinking hard. Tell your eye doctor about asthma, COPD or a slow pulse before starting, and list eye drops when asked about your medicines, since they count.

Beta Blockers in Pregnancy

Atenolol, a selective drug, is generally avoided in pregnancy because of links with poor fetal growth, slow fetal heart rate and low blood sugar.⁴⁹ The selective label says nothing about how a drug affects a developing baby, which depends on how that specific drug crosses to the baby and what it does there. Other beta blockers are used in pregnancy when needed.

If you take a beta blocker and plan or discover a pregnancy, ask your doctor about switching rather than stopping, since stopping abruptly can harm your own heart and blood pressure. Raise it at the first pregnancy visit, or before you start trying.

1
PubMed Central. Propranolol: A 50-Year Historical Perspective ↩︎
2
PubMed. Beta-blockers: Historical Perspective and Mechanisms of Action ↩︎
3
International Journal of Pharmaceutical Sciences. An Overview On Three Generation Beta Blockers ↩︎
4
International Journal of Pharmaceutical Sciences. An Overview On Three Generation Beta Blockers ↩︎
5
PubMed. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors ↩︎
6
Taylor & Francis Online / Current Medical Research and Opinion. β-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications ↩︎
7
International Journal of Pharmaceutical Sciences. An Overview On Three Generation Beta Blockers ↩︎
8
International Journal of Pharmaceutical Sciences. An Overview On Three Generation Beta Blockers ↩︎
9
PubMed. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action ↩︎
10
The Cardiology Advisor. Beta Blockers ↩︎
11
PubMed. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action ↩︎
12
Best Practice Journal. What Is Beta Blocker Selectivity and Why Does It Matter? ↩︎
13
PubMed. Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective ↩︎
14
PubMed. Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective ↩︎
15
PubMed. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials ↩︎
16
PubMed. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials ↩︎
17
PubMed. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials ↩︎
18
PubMed. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials ↩︎
19
PubMed. Cardioselective beta-blockers for reversible airway disease ↩︎
20
PubMed Central. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions ↩︎
21
PubMed Central. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions ↩︎
22
CV Pharmacology. Beta-Adrenoceptor Antagonists ↩︎
23
AMBOSS. Beta blockers ↩︎
24
PubMed Central. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy ↩︎
25
PubMed Central. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy ↩︎
26
PubMed Central. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure ↩︎
27
Taylor & Francis Online / Current Medical Research and Opinion. β-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications ↩︎
28
Best Practice Journal. What Is Beta Blocker Selectivity and Why Does It Matter? ↩︎
29
PubMed. The influence of different beta-blocking drugs on the peripheral circulation in Raynaud’s phenomenon and in hypertension ↩︎
30
PubMed. Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease ↩︎
31
Best Practice Journal. What Is Beta Blocker Selectivity and Why Does It Matter? ↩︎
32
PubMed. Effects of beta-blockers on glucose and lipid metabolism ↩︎
33
PubMed. Effects of beta-blockers on glucose and lipid metabolism ↩︎
34
PubMed. Effect of beta blockers on blood lipid profile ↩︎
35
Clinical Diabetes. Reexamining Misconceptions About β-Blockers in Patients With Diabetes ↩︎
36
PubMed Central. β‐Blockers and risk of neuropsychiatric disorders: A systematic review and meta‐analysis ↩︎
37
PubMed. Relevance of intrinsic sympathomimetic activity for beta blockers ↩︎
38
PubMed Central. Influence of intrinsic sympathomimetic activity of β-adrenoceptor blockers on the heart rate and blood pressure responses to graded exercise ↩︎
39
DEVELOPMENTAL MEDICO-LIFE-SCIENCES. Beta-Blockers and Mortality Reduction in Heart Failure: A Systematic Review of Randomized Controlled Trials ↩︎
40
European Heart Journal. The Role of Selective Beta Blocker in Heart Failure Management ↩︎
41
DEVELOPMENTAL MEDICO-LIFE-SCIENCES. Beta-Blockers and Mortality Reduction in Heart Failure: A Systematic Review of Randomized Controlled Trials ↩︎
42
PubMed. Beta-blockers in the treatment of neurological and psychiatric disorders ↩︎
43
PubMed. Beta-blockers in the treatment of neurological and psychiatric disorders ↩︎
44
PubMed. Beta-blockers in the treatment of neurological and psychiatric disorders ↩︎
45
PubMed. Severe systemic adverse reactions to ophthalmic timolol in a CYP2D6 homozygous *4 allele carrier: a case report ↩︎
46
PubMed. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops ↩︎
47
PubMed. Systemic side effects associated with the ophthalmic administration of timolol ↩︎
48
PubMed. Systemic side effects associated with the ophthalmic administration of timolol ↩︎
49
American College of Cardiology. Heart Failure Medication Recommendations During Pregnancy and Breastfeeding ↩︎